Best Rising Stocks To Buy Right Now

Michael Kitces

A new paper that suggests rising equity exposure in retirement may in fact lead to better outcomes has set the web abuzz.

Financial planning literati Wade D. Pfau, professor of retirement income at The American College, and Michael Kitces, partner and director of research at Pinnacle Advisory Group, released a paper earlier this fall entitled “Reducing Retirement Risk with a Rising Equity Glidepath.”

The paper turns conventional retirement income strategy on its head. Mr. Kitces and Mr. Pfau observe that a U-shaped glide path in retirement — one in which equities are at their lowest allocation in the retirement transition and then rise afterward — is preferable to the standard downward slope of equity allocation as a client ages.

Hot Mid Cap Companies To Own For 2015: P & F Industries Inc.(PFIN)

P&F Industries, Inc., through its subsidiaries, manufactures and sells tools and hardware products in the United States. The company operates in two segments, Tools and Other Products (Tools) and Hardware and Accessories (Hardware). The Tools segment manufactures, imports, and sells pneumatic hand tools, primarily for the industrial, retail, and automotive markets. Its product line includes sanders, grinders, drills, saws, impact wrenches, and pavement breakers; compressor air filters; and pipe and bolt dies, pipe taps, wrenches, vises and stands, pipe and tubing cutting equipment, hydrostatic test pumps, and replacement electrical components for pipe cutting and threading machines. This segment sells its products under the Florida Pneumatic, Universal Tool, ATP, Thaxton, THOR, and Eureka brand names to distributors, retailers, and private label customers through in-house sales personnel and manufacturers' representatives. The Hardware segment manufactures and imports door , window, and fencing hardware, including rollers, hinges, window operators, sash locks, custom zinc castings, and door closers. This segment also manufactures and imports interior wood and iron stair components, and related accessories, as well as kitchen and bath hardware; and manufactures stair products and distributes staircase components. Its products are sold through in-house sales personnel and manufacturers? representatives to distributors, retailers, and OEM customers. The company was founded in 1959 and is based in Melville, New York.

Advisors' Opinion:

• [By Monica Gerson]

  P&F Industries (NASDAQ: PFIN) is expected to report its quarterly results.

  INSYS Therapeutics (NASDAQ: INSY) is projected to report its Q1 earnings at $0.28 per share on revenue of $45.63 million.

Best Rising Stocks To Buy Right Now: Oleo e Gas Participacoes SA (OGXP3)

Oleo e Gas Participacoes SA, formerly Centennial Asset Participacao Corumba SA, is a Brazil-based company involved in the oil and natural gas industry. The Company and its subsidiaries are primarily engaged in the research, mining, refining, processing, trade and transportation of oil and natural gas. The Company�� subsidiaries participated in a number of concessions in the Brazil and Colombia. On November 21, 2013, processing of judicial recovery was approved for the Company and OGX Petroleo e Gas SA, following decision of the Corporate Court of Capital of the State of Rio de Janeiro. Advisors' Opinion:

• [By Harry Suhartono]

  The MSCI Emerging Markets Index fell 0.3 percent to 1,004.66. OGX Petroleo e Gas Participacoes SA (OGXP3) plunged to a record low in Sao Paulo as two people with knowledge of the matter said the oil producer is considering filing for bankruptcy protection within a month. India�� rupee snapped a three-day gain. Polish yields sank to an eight-week low on bets Zyta Gilowska�� successor on the central bank�� rate-setting panel will be reluctant to tighten monetary policy in 2014.

Best Rising Stocks To Buy Right Now: iShares Russell 2000 Index Fund (IWM)

iShares Russell 2000 Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Russell 2000 Index (the Index). The Index measures the performances of the small capitalization sector of the United States equity market. The Index includes approximately 8% of the market capitalization of all publicly traded United States equity securities.

The Index is a subset of the Russell 3000 Index, and serves as the underlying index for the Russell 2000 Growth and Value Index series. The Index is a capitalization-weighted index of the approximately 2000 smallest companies in the Russell 3000 Index. The Fund uses a representative sampling strategy in seeking to track the Index. iShares Russell 2000 Index Fund's investment advisor is Barclays Global Fund Advisors.

Advisors' Opinion:

• [By Ben Levisohn]

  The SPDR S&P 500 ETF (SPY) gained 2.3% in May, while the SPDR Dow Jones Industrial Average ETF (DIA) rose 1.2%, and even the beaten-down iShares Russell 2000 ETF (IWM) finished up 0.8% last month. Last but not least, the PowerShares QQQ (QQQ), which tracks the Nasdaq 100, rose a whopping 4.5%.

• [By Tom Aspray]

  No matter what happens in the last two weeks of the year, 2013 will clearly stand out as a buy-and-hold year with index funds as the star performers. The iShares Russell 2000 Index (IWM) is currently up 34.1% YTD, followed closely by the 33% gain in the PowerShares QQQ Trust (QQQ).

• [By Chris Ciovacco]

  Investment Implications
  The Fed's desire to taper their bond purchases is concerning and something that we will monitor closely. However, the known desire to taper has not yet shown up in the credit markets in the form of risk aversion as it did in 2007 and 2011 prior to sharp declines in stocks. As long as that is the case, we will continue to favor stocks (SPY) over bonds (AGG). We will also hold our positions in leading sectors such as financials (XLF), technology (QQQ), and small caps (IWM). If the messages from the markets change, we are happy to migrate toward a more conservative stance.

Best Rising Stocks To Buy Right Now: Cambridge Bancorp (CATC)

Cambridge Bancorp, incorporated on December 23, 1982, is a state chartered, federally bank holding company in Cambridge. The Company�� reportable operating segment consists of commercial banking, consumer banking, and trust and investment management services. Cambridge Trust Company (the Bank) is a subsidiary of the Company. The Bank offers a range of commercial and consumer banking services through its network of 12 service banking offices in Massachusetts. The Bank is engaged in the business of attracting deposits from the public and investing those deposits. The Bank invests those funds in various types of loans, including residential and commercial real estate, and a variety of commercial and consumer loans. The Bank also invests its deposits and borrowed funds in investment securities and has three wholly owned Massachusetts Security Corporations, CTC Security Corporation, CTC Security Corporation II and CTC Security Corporation III.

Lending activities

The Bank originates loans to businesses and individuals on both a collateralized and an uncollateralized basis. The Bank�� customer base is concentrated in eastern Massachusetts. The majority of loans to individuals are collateralized by residential real estate, marketable securities or other assets.

Investment activities

The Bank invests in United States government sponsored enterprise (GSE) obligations, mortgage-backed securities, mutual funds and municipal securities. As a member of the Federal Home Loan Bank (FHLB) of Boston (the FHLB Boston), the Bank is required to invest in stock of the FHLB Boston in an amount based upon itsadvances from the FHLB Boston.

Sources of Funds

The Bank attracts deposits, such as demand deposits (non-interest bearing), interest bearing checking, money market, savings, certificates of deposit under $100,000 and certificates of deposit $100,000 or greater. Its short term borrowings consist of treasury, tax and loan notes, and FHLB Bost! on overnight borrowings.

Advisors' Opinion:

• [By CRWE]

  Today, CATC has shed (-0.26%) down -0.10 at $38.90 with 500 shares in play thus far (ref. google finance Delayed: 11:24AM EDT July 22, 2013), but don�� let this get you down.

  Cambridge Bancorp previously reported unaudited net income of $3,475,000 for the second quarter of 2013 compared to $3,451,000 for the same quarter in 2012. The slight increase in earnings was primarily attributable to growth in noninterest income, offset by a decrease in net interest income. Diluted earnings per share were $0.89 for the second quarter of 2013, unchanged versus for the same quarter in 2012. For the six months ended June 30, 2013, unaudited net income was $6,806,000 compared to $6,736,000 for the first half of 2012. Diluted earnings per share were $1.75 for the first six months of 2013 versus $1.74 for the same period in 2012.

• [By CRWE]

  Last Friday, CATC previously surged (+0.26%) up +0.10 at $39.00 with 600 shares in play at the close (ref. google finance July 26, 2013 ��Close).

  Cambridge Bancorp previously reported unaudited net income of $3,475,000 for the second quarter of 2013 compared to $3,451,000 for the same quarter in 2012. The slight increase in earnings was primarily attributable to growth in noninterest income, offset by a decrease in net interest income. Diluted earnings per share were $0.89 for the second quarter of 2013, unchanged versus for the same quarter in 2012. For the six months ended June 30, 2013, unaudited net income was $6,806,000 compared to $6,736,000 for the first half of 2012. Diluted earnings per share were $1.75 for the first six months of 2013 versus $1.74 for the same period in 2012.

Best Rising Stocks To Buy Right Now: Equinix Inc.(EQIX)

Equinix, Inc. provides data center services for the protection and connection of information assets to enterprises, financial service companies, and content and network service providers worldwide. It connects businesses with partners and customers through a platform of high performance data centers, containing dynamic ecosystems and the broadest choice of networks. The company operates International Business Exchange (IBX) centers, or IBX data centers, across 38 markets in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. Equinix offers data center services, including premium data center co-location; interconnection and exchange services; network connectivity; business continuity; and outsourced IT infrastructure services. The company connects approximately 4,000 enterprises, cloud, digital content, and financial companies, including 680 network service providers to help them grow their businesses, improve application performance, and protect their vita l digital assets. It markets its products and services through direct sales force and channel marketing program. Equinix was founded in 1998 and is headquartered in Redwood City, California.

Advisors' Opinion:

• [By Steve Sears]

  New stocks in what Goldman calls the “Hedge Fund VIP list,”�include Actavis (ACT), Baidu (BIDU), Berkshire Hathaway (BRK.B), Crown Castle International (CCI), Entergy Louisiana (ELB), �Equinix (EQIX), Facebook (FB), Fleetcor Technologies (FLT), W.R. Grace (GRA), MetLife (MET), Macquarie Infrastructure (MIC), Micron (MU), Time Warner Cable (TWC), and Time Warner (TWX).

Best Rising Stocks To Buy Right Now: BioTime Inc (BTX)

BioTime, Inc., incorporated on November 30, 1990, is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (hES) cell lines, and royalties from Hextend. Its focus is to provide regenerative therapies for age-related degenerative diseases. In January 2011, the Company acquired the assets of Cell Targeting, Inc. (CTI), a biotechnology company focused on methods of painting molecules on the surface of cells, which in turn causes the cells to adhere to particular tissues, such as those afflicted with disease. On March 21, 2011, the Company acquired Glycosan BioSystems, Inc. (Glycosan) through a merger of Glycosan with OrthoCyte Corporation (OrthoCyte). Through the merger, OrthoCyte acquired all of Glycosan�� assets, including Glycosan�� Hystem hydrogel product line. In March 2011, the Company entered into an agreement with XenneX, Inc., pursuant to which it organized LifeMap Sciences, Inc. (LifeMap), a subsidiary formed to advance the development and commercialization of its human embryonic stem (hES) cell data base. In August 2011, four hES cell lines (ESI-035, ESI-049, ESI-051 and ESI-053) developed by its subsidiary ES Cell International (ESI) were approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. In May 2012, the Company acquired XenneX, Inc., through a merger of XenneX into LifeMap Sciences. In September 2012, the Company formed a wholly owned subsidiary, BioTime Acquisition Corporation. In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets to Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.

HyStem is a biomaterial, which mimics the human extracellular matrix, which is the network of molecules surrounding cells in organs and tissues which is essent! ial to cellular function. Its HyStem hydrogels may have other applications when combined with the diverse and scalable cell types its scientists have isolated from hES cells. HyStem-Rx is a clinical grade formulation of HyStem-C, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. Its subsidiary, OncoCyte Corporation, is developing PanC-Dx, a non-invasive blood-based cancer screening test designed to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check -ups. BioTime Asia, Limited (BioTime Asia) sells products for research use and may develop therapies to treat cancer and neurological and orthopedic diseases in Asia. OrthoCyte Corporation (OrthoCyte) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (ReCyte Therapeutics) is developing therapies for age-related cardiovascular and blood disorders. Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences), is a biotechnology company focused on developing stem cell-based therapies for retinal and other neurological disorders, including the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. LifeMap Sciences, Inc. (LifeMap) is advancing the development and commercialization of our embryonic stem cell database and plans to make the database available for the marketing of research products and for use by stem cell researchers at pharmaceutical and biotechnology companies and other institutions via paid subscriptions or on a fee per use basis.

The Company�� blood plasma expander product, Hextend, is a physiologically balanced intravenous solution used in the treatment of hypovolemia, a condition caused by low blood volume, often from blood loss during surgery or injury. Hextend maintains circulatory system fluid volume and blood pressure, and keeps vital organs perfused during surgery and t! rauma car! e. Hextend is manufactured and distributed in the United States by Hospira, Inc., and in South Korea by CJ CheilJedang (CJ), under license from it.

Human Embryonic Stem Cell Lines for Research Use

Combined with the Company�� ACTCellerate technology, it derives of a range of markets human embryonic progenitor cells (hEPCs). ESI�� six current good manufacturing practices (cGMP) hES cell lines have been approved by the NIH for inclusion in the Human Embryonic Stem Cell Registry, which renders those cell lines eligible for use in federally funded research. The ESI hES cell lines are available for purchase through www.biotimeinc.com. It also markets hEPCs developed using ACTCellerate technology. Its hEPCs are also available for sale through www.biotimeinc.com. It derived the complete genome sequence of five of the ESI hES cell lines to facilitate the development of products derived from these cell lines. It has made these GMP-grade cell lines, along with certain documentation and complete genomic deoxyribonucleic acid (DNA) sequence information, available for sale.

The Company offers human stem cell products and technology that can be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. It has developed research and clinical grade hES cell lines, which it markets for both basic research and therapeutic product development. It also markets human embryonic progenitor cell (hEPCs) developed using ACTCellerate technology. These hEPCs are purified lineages of cells, which are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The ACTCellerate cell lines are also available for purchase through http://www.biotimeinc.com.

Human Embryonic Progenitor Cells

Through the Company�� subsidiary ReCyte Therapeutics, it had a license from Advanced Cell Technology, Inc. (ACT) to use ACTCellerate technology, and the rights to market more than 200 human c! ell types! made using that process. ACTCellerate allows the rapid isolation of hEPCs, which are cells that are intermediate in the developmental process between embryonic stem cells and fully differentiated cells.

Through an agreement with ReCyte Therapeutics, Millipore Corporation became a global distributor of ACTCellerate hEPC lines. In addition to the products, which it is co-marketing with Millipore, it offers 92 other ACTCellerate hEPC lines for purchase at www.biotimeinc.com. Through its subsidiary LifeMap, it provides online biomedical database services to increase awareness of molecular markers and diverse cell types comprising its ACTCellerate hEPC lines. It also focuses to market additional cell types manufactured with its PureStem technology. PureStem cell lines are produced by the exogenous expression of specific transcription factors, which regulate the differentiation of cell types from hES or induced pluripotent stem (iPS) cells. BioTime Asia has an agreement with Shanghai Genext Medical Technology Co., Ltd. to sell ACTCellerate hEPC lines and related ESpan growth media to the medical and biological research communities in China, Taiwan, Hong Kong, and Macau on an exclusive basis. The marketing agreement includes provisions for an initial stocking inventory and annual milestones to maintain exclusivity. The Company�� California Institute of Regenerative Medicine (CIRM)-funded research addresses the need for industrial scale production of purified therapeutic cells.

hES Cells Carrying Genetic Diseases

The Company focuses to add to its product line muscle progenitor cells produced from five hES cell lines carrying genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. It obtained the diseased hES cell lines from Reproductive Genetics Institute (RGI).

ESpan Cell Growth Media

The Company is marketing a range of! cell-gro! wth media products called ESpan. These growth media are optimized for the growth of hEPC types. Cells need to be propagated in liquid media, in both the laboratory setting, where basic research on stem cells is performed, and in the commercial sector. Its ESpan products are marketed through Millipore and Genext.

ESpy Cell Lines

The Company focuses for development of ESpy cell lines. The ability of the ESpy cells to emit light will allow researchers to track the location and distribution of the cells in both in vitro and in vivo studies.

HyStem Hydrogel for Research and HyStem-Rx for Cell Delivery Medical Devices

HyStem is a patented biomaterial that mimics the ECM, the network of molecules surrounding cells in organs and tissues that is essential to cellular function. Its HyStem technology forms the foundation for stem cell delivery products in both the adult and embryonic stem cell marketplace, including products manufactured using its ACTCellerate technology. As an injectable product, HyStem-Rx may address need in cosmetic and reconstructive surgeries and other procedures by transplanting adipose derived cells or other adult stem cells. The transfer of cells in HyStem-Rx localizes the transplanted cells at the intended site and by providing a three-dimensional scaffold upon which cells can rebuild normal tissue. HyStem-Rx may support other emerging cell and tissue transplant therapies, such as those derived from hES and iPS cells, in addition to its potential application in the treatment of a range of conditions such as osteoarthritis, brain tumors, stroke, bone fracture, and wounds.

Advisors' Opinion:

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company BioTime (NYSEMKT: BTX  ) has received the dreaded one-star ranking.

• [By John Udovich]

  Stem cell stocks have not exactly been the best performers lately in part because the controversy over their use has died down over the years while major breakthroughs have been few or far between, but the industry along with small cap stem cell stocks Pluristem Therapeutics Inc (NASDAQ: PSTI), BioTime, Inc (NYSEMKT: BTX) and BioRestorative Therapies (OTCBB: BRTX) are still quietly producing their share of news or minor breakthroughs worth taking note of. Just consider the following stem cell news or news from small cap players in the sector:

Best Rising Stocks To Buy Right Now: RAIT Financial Trust(RAS)

RAIT Financial Trust operates as a self-managed and self-advised real estate investment trust (REIT). The company, through its subsidiaries, invests in, manages, and services real estate-related assets with a focus on commercial real estate. It also offers a set of debt financing options to the commercial real estate industry along with fixed income trading and advisory services. In addition, RAIT Financial Trust owns and manages a portfolio of commercial real estate properties, and manages real estate-related assets for third parties. The company qualifies as a REIT for federal income tax purposes. As a REIT, it would not be subject to federal income tax to the extent that it distributes at least 90% of its taxable income to its shareholders. RAIT Investment Trust was founded in 1997 and is based in Philadelphia, Pennsylvania.

Advisors' Opinion:

• [By Marc Bastow]

  Commercial real estate holding real estate investment trust (REIT) RAIT Financial (RAS) raised its quarterly dividend 7% to 16 cents per share, payable on Jan. 31 to share holders of record as of Jan. 7.
  RAS Dividend Yield: 7.48%

• [By Eric Volkman]

  RAIT Financial Trust (NYSE: RAS  ) investors will be getting slightly more than they did last quarter, as a reward for putting their faith in the company (NYSE: RAS  ) . The real estate investment trust has declared a common stock dividend of $0.13 per share, to be handed out on July 31 to shareholders of record as of July 12.�That amount is $0.01, or 8%, higher than RAIT's previous distribution of $0.12, which was paid in April. Prior to that, the firm dispensed $0.10 per share.

• [By Thomas Sobon]

  Instead of expressing my thoughts in vague generalities, let me be specific and tell you what I am actually doing on a real time basis to cope with the market dynamics occurring right now: I have a core position in one stock, which is the RAIT Financial Trust (RAS). Its size is about 60% of what I would consider to be a "full" position. I also have a lot of cash that I intend to use for trading purposes. Last Friday I sold shares of RAS at $7.55 which I bought on Monday with a low-ball bid of $7.11, so my gain on the trade was 6.2%. In early trading yesterday (Monday July 1) RAS is priced at $7.67, up from where I sold on Friday. That's great news because I accomplished what I wanted to do with the trade and now paper profit on the core shares in my portfolio is increasing.

• [By Marc Bastow]

  Commercial real-estate loan originator and real estate investment trust RAIT Financial Trust (RAS) raised its quarterly dividend 6% to 17 cents per share, payable April 30 to shareholders of record as of April 4. At more than an 8% yield, RAS stock has the highest yield on this week’s list of dividend stocks.
  RAS Dividend Yield: 8.14%.